period, ACL received approximately one-hundred and eleven comments on many aspects of the ILS PPR. A public comment and ACL's response to comment table is listed in Supporting Statement A.

Estimated Program Burden: ACL estimates the burden of this collection of information as follows:

The PPR will be sent to representatives of fifty states, the District of Columbia, Puerto Rico, American Samoa, the Commonwealth of the Northern Mariana Islands, Guam, and US Virgin Islands. The approximate burden for completion is thirty-six hours per respondent, which includes time to review the instructions, read the questions, and complete responses. This results in a total annual burden estimate of 2,016 hours.

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Number of respondents	Responses per respondent	Average burden hours per response	Total burden hours
56	1	36	2,016

Dated: March 19, 2024.

Alison Barkoff,

Principal Deputy Administrator for the Administration for Community Living, performing the delegable duties of the Administrator and the Assistant Secretary for Aging.

[FR Doc. 2024–06207 Filed 3–22–24; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Community Living

Agency Information Collection Activities; Submission for OMB Review; Public Comment Request; ACL Program Performance Report Generic Information Collection, OMB Control Number 0985–NEW

AGENCY: Administration for Community Living, HHS.

ACTION: Notice.

SUMMARY: The Administration for Community Living is announcing that the proposed collection of information listed above has been submitted to the Office of Management and Budget (OMB) for review and clearance as required under the Paperwork Reduction Act of 1995. This 30-day notice collects comments on the information collection requirements related to the ACL Program Performance Report Generic Information Collection, OMB 0985–NEW.

DATES: Comments on the collection of information must be submitted electronically by 11:59 p.m. (EDT) or postmarked by April 24, 2024.

ADDRESSES: Submit written comments and recommendations for the proposed information collection within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find the information collection by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function. By mail to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW, Rm. 10235, Washington, DC 20503, Attn: OMB Desk Officer for ACL.

FOR FURTHER INFORMATION CONTACT: Shannon Skowronski, Administration for Community Living, *evaluation@acl.hhs.gov,* (202) 795–7316.

SUPPLEMENTARY INFORMATION: In compliance with the Paperwork Reduction Act (44 U.S.C. 3506), the Administration for Community Living (ACL) has submitted the following proposed collection of information to OMB for review and clearance. In 1965, the Older Americans Act (OAA) was passed in response to concerns by policymakers about a lack of community social services for older adults. The OAA established authority for grants for community planning and social services, research and development projects, and personnel training in the field of aging. The Elder Justice Act (EJA), passed in 2010, is the first comprehensive legislation to address the abuse, neglect, and exploitation of older adults at the Federal level. OAA and EJA programs help advance ACL's mission of supporting the independence, well-being, and health of older adults, older adults with disabilities, and their families and caregivers. This proposed information collection will gather program performance data for ACL formula and competitive grant programs authorized by the Older Americans Act (OAA) and the Elder Justice Act (EJA), as required by and in accordance with Public Law 116–131 and 42 U.S.C. chapter 7, subchapter XX, division B (authorizing legislation); 45 CFR 75.342 (monitoring and reporting program performance); 45 CFR 75.301 (performance measurement); and the GPRA Modernization Act of 2010 (Pub. L. 111–352, sec. 12). The collection of program performance data is required for all ACL grantees, including grants authorized by the OAA and EJA, to: (1) monitor achievement of program performance objectives; (2) identify areas of performance that may benefit from technical assistance and/or corrective action; 3) establish program policy and direction; and (4) prepare responses and reports for Congress, the Office of Management and Budget (OMB), other federal departments, and public and private agencies, including legislatively required reports.

ACL consistently looks for ways to streamline the collection of required program performance data. The proposed *ACL Program Performance Report Generic Information Collection* would provide an efficient mechanism for the collection of a core set of program performance data elements across OAA and EJA authorized programs necessary to ensure each programs indicators, demographics, priorities, and objectives are being achieved. The collection of this core set of performance elements will enable ACL to analyze program performance broadly across its grantee portfolio, while minimizing grantee reporting burden. Program offices will be given the opportunity to submit, for review and approval under this generic clearance, PPRs for their programs that address the core program performance elements.

Comments in Response to the 60-Day Federal Register Notice

A 60-day notice published in the **Federal Register** on December 5, 2023, at 88 FR 84335. ACL received two public comments. A summary of the comments and the ACL response is provided below:

Comment One: Suggest including more specific instructions for completing the elements in the proposed ACL PPR template.

ACL response: While ACL appreciates this suggestion, the instructions for

completing the elements must be somewhat broad to account for differences in the goals, objectives, and activities across the programs.

Comment Two: Request confirmation that the grantee will be responsible for submitting a comprehensive PPR each reporting period to ACL (as opposed to having grantees' subcontractors *each* submit individual reports to ACL).

ACL response: Although grantees could work with their subcontractors to gather information to complete their PPR, grantees would be responsible for submitting a comprehensive PPR to ACL for the specified reporting period.

Estimated Program Burden

ACL estimated total annual burden for this generic IC is 50,223.60 hours. This estimate is based on the current number of grantees for the OAA and EJA programs below, consideration of the program performance information necessary to ensure adequate progress toward program goals, and previous experience with program performance reporting.

Respondent/data collection activity	Number of respondents	Responses per respondent	Hours per response	Annual burden hours
State Formula Grantees	112	1	70.3	7,873.60
Tribal Formula Grantees	282	1	60	16,920
Competitive Grantees	1,189	2	10	23,780
Veteran Organization Competitive Grantees	275	12	0.5	1,650
Total Annual Hours				50,223.60

Dated: March 19, 2024.

Alison Barkoff,

Principal Deputy Administrator for the Administration for Community Living, performing the delegable duties of the Administrator and the Assistant Secretary for Aging.

[FR Doc. 2024–06208 Filed 3–22–24; 8:45 am]

BILLING CODE 4154–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–N–3615]

Martin Valdes: Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Martin Valdes, M.D., from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Dr. Valdes was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product under the FD&C Act. Dr. Valdes was given notice of the proposed permanent debarment and an opportunity to request a hearing to show why he should not be debarred. As of January 7, 2023 (30 days after receipt of the notice), Dr. Valdes had not responded. Dr. Valdes's failure to respond and request a hearing within the prescribed timeframe constitutes a waiver of his right to a hearing concerning this action.

DATES: This order is applicable March 25, 2024.

ADDRESSES: Any application by Dr. Valdes for special termination of debarment under section 306(d)(4) of the FD&C Act (21 U.S.C. 335a(d)(4)) may be submitted at any time as follows:

Electronic Submissions

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. An application submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your application will be made public, you are solely responsible for ensuring that your application does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your application, that information will be posted on *https://www.regulations.gov.*
- If you want to submit an application with confidential information that you do not wish to be made available to the public, submit the application as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For a written/paper application submitted to the Dockets Management Staff, FDA will post your application, as well as any attachments, except for information submitted, marked, and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All applications must include the Docket No. FDA–2023–N–3615. Received applications will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit an application with confidential information that you do not wish to be made publicly available, submit your application only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of your application. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. Any information marked as ''confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: *https://*